Pfizer/J&J Alzheimer's Drug Should Get Longer Patent Life, Appeals Court Says
Executive Summary
An appeals court ruled that the Patent and Trademark Office had miscalculated the patent term extension owed to Pfizer and Johnson & Johnson for delays in prosecuting the patent on the investigational Alzheimer's drug bapineuzumab